Generic API Suppliers vs Branded APIs: How Formulators and Importers Should Choose the Right Source

Introduction: The Molecule Is the Same. The Supplier Is Not.

A procurement manager at a nutraceutical formulator is comparing two quotations for the same mineral ingredient. Both suppliers list the same chemical name, the same CAS number and the same pharmacopoeial grade. One supplier is tied to a branded, originator-linked supply chain. The other is a generic, merchant-market manufacturer that sells to many customers on open commercial terms. The price gap is visible. The quality gap, if there is one, is not.

This is the real question behind "branded vs generic API." It is rarely about whether the molecule is different. It is about which supplier can show, on paper and in every batch, that the material will behave the same way each time it arrives.

The commercial scale of the generic market explains why this question matters. According to the Association for Accessible Medicines (AAM), generic and biosimilar medicines accounted for 90 percent of US prescriptions but only 12 percent of drug spending in 2024, and saved the US healthcare system $467 billion that year (AAM, 2025 U.S. Generic & Biosimilar Medicines Savings Report, September 2025). Behind every one of those prescriptions is an active pharmaceutical ingredient (API) that someone had to source.

This guide explains what "branded" and "generic" actually mean at the API level, where genuine quality differences can appear, how to compare originator-linked and merchant-market supply, and what a buyer should check before qualifying a generic API supplier. It uses regulatory text and official data, with every source listed at the end.

1. What "Branded" and "Generic" Mean at the API Level

The words "branded" and "generic" come from the finished-medicine world. A branded medicine is sold under a proprietary name by the company that developed it. A generic medicine is sold after the originator's exclusivity ends, and it must contain the same active ingredient as the reference product.

At the API level the words need translating, because an API is an ingredient, not a medicine. In practice, buyers use them in two ways.

Originator-Linked API Supply

This is API made by, or made exclusively for, the company that owns the branded product. It is often manufactured to that company's own process and specification, and it is usually not sold on the open market. Formulators that make a branded product rely on it, but a third-party formulator typically cannot buy it freely.

Generic or Merchant-Market API Supply

This is API made by a manufacturer that sells to many formulators on open commercial terms. The manufacturer owns its process, publishes a specification, and supplies batch documents with each shipment. Most formulators making generic and nutraceutical products source from this group.

Not the Same as "Branded Generic"

A third term often causes confusion. A "branded generic" is a finished product: a generic medicine marketed under a brand name by a generic maker. It describes the label on a pack, not the origin of an API. This guide is about the ingredient, not the pack.

2. The Sameness Principle: Why the Molecule Does Not Change

The most important fact for any buyer is that regulators already require a generic product to contain the same active ingredient as its reference product.

In the United States, 21 CFR 314.94(a)(5) requires an applicant for an abbreviated new drug application (ANDA) to state that, for a single-ingredient drug, "the active ingredient is the same as that of the reference single-active-ingredient listed drug." FDA's own public page on generic medicines says the same thing in plain language: "The active ingredient in the generic medicine is the same as in the brand-name drug/innovator drug," and generic applicants must show that the product is bioequivalent to the brand-name medicine (FDA, Generic Drug Facts).

FDA has also published a draft guidance titled Sameness Evaluations in an ANDA — Active Ingredients (November 2022, docket FDA-2022-D-0697). It is non-binding and marked "not for implementation," but it confirms the legal basis: section 505(j)(2)(A)(ii) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.94(a)(5).

What Sameness Does and Does Not Cover

Sameness answers one question: is the active ingredient the same substance? It does not mean every supplier's material is identical in every physical and impurity characteristic. Two batches of the same molecule can differ in particle size, impurity profile, moisture content or residual solvents, and still be the same active ingredient.

That is why the supplier's controls matter. The molecule is a given. The quality system around it is the variable.

Inactive Ingredients Are Handled Separately

Under 21 CFR 314.94(a)(9), a generic applicant must identify and characterize the inactive ingredients in the proposed product and show they do not affect safety or efficacy. For certain dosage forms, such as parenteral and ophthalmic products, the rules on inactive ingredients are stricter. This is a finished-product matter, but it shows that regulators treat the active ingredient and everything around it as separate questions.

3. Where Real Differences Show Up Between Suppliers

If the molecule is the same, what should a buyer actually compare? Five areas account for most real differences.

1. Impurity Profile and Elemental Impurities

Different synthesis routes and raw materials leave different trace impurities. For mineral and metal-salt ingredients, elemental impurities are especially relevant. The ICH Q3D guideline, now in Revision 2 with a legal effective date of 24 September 2022 in the EU, sets out a risk-based process for assessing and controlling elemental impurities. The European Medicines Agency notes that its implementation strategy is intended for applicants, drug product, drug substance and excipient manufacturers, as well as regulators (EMA, ICH Q3D Elemental impurities).

For a buyer, the practical question is whether the supplier can provide the data a formulator needs to complete its own elemental-impurity risk assessment.

2. Pharmacopoeial Grade and Monograph Compliance

A material may be sold to the standard of a recognized pharmacopoeia such as the USP, BP, EP or IP, or to a supplier's own in-house specification. These are not equivalent. For example, the USP-NF monograph for Ferrous Fumarate (listed under the Dietary Supplement monographs) states that the material "contains NLT 97.0% and NMT 101.0% of ferrous fumarate (C4H2FeO4), calculated on the dried basis." A buyer should always confirm which monograph and which edition a supplier tests against, because monographs are revised over time.

3. Physical Properties

Particle size distribution, bulk density, flowability and moisture content can affect how an ingredient blends, compresses or dissolves in a formulation. Two suppliers can both meet the same chemical assay and still deliver powders that behave differently on a production line. This is a general technical consideration. Buyers should request a technical data sheet and, where relevant, test samples in their own process.

4. GMP and Quality System

ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, is the international reference for API manufacturing quality. FDA's published version (August 2001) covers APIs used in human drug products, including receipt of materials, production, packaging, labelling, quality control, release, storage and distribution. A supplier that works under a documented GMP system gives a buyer something to audit against.

5. Documentation and Change Control

Batch-specific Certificates of Analysis, material safety data sheets, a clear specification and a process for notifying customers about changes are the working tools of supplier qualification. A supplier that changes a raw-material source or process step without notice can create a regulatory problem for the formulator downstream. Change control is a supplier-quality question, not a branded-versus-generic question.

4. Originator-Linked vs Merchant-Market API Supply

The table below compares the two supply models on the points a procurement team usually weighs.

Neither model is automatically better. A formulator making a product under an originator's licence will use the originator-linked source. A formulator making a multi-source generic or nutraceutical product will almost always buy on the merchant market, and the decision then turns on supplier quality, not on whether the API has a brand attached.

Choosing Between the Two: Four Common Scenarios

Scenario 1: You make a product under an originator's licence. The licence usually names the API source. Your choice is made for you, and the work is in managing that single relationship well.

Scenario 2: You make a multi-source generic. The merchant market is your normal route. Your effort goes into qualifying two suppliers, setting a clear specification and monitoring batch-to-batch consistency.

Scenario 3: You make a nutraceutical or fortification product. The ingredient has no originator chain. The relevant questions are the grade for your end use, the documents your market requires and the physical properties your process needs.

Scenario 4: You are launching a new market. Start with the destination's document requirements, then choose a supplier that can provide them. Import rules differ by country, so check the requirements of each market before the first order.

5. Cost, Continuity and Supply Risk

Why Generic Markets Compete on Price

Once exclusivity ends, many manufacturers can supply the same molecule, and competition lowers prices. AAM's 2024 data shows the scale of the difference: generics accounted for 3.9 billion prescriptions at a cost of $98 billion, while brand medicines accounted for 435 million prescriptions at a cost of $700 billion. This is an industry-association figure for the US market and should be read as such, but the direction is clear. High volume and many suppliers keep unit costs low.

Single-Source Risk

A product that depends on one supplier is exposed to everything that can go wrong at that supplier: a plant shutdown, a raw-material shortage, a regulatory finding or a logistics disruption. Qualifying a second source is a standard risk-control step in procurement. Merchant-market APIs make that possible because more than one qualified manufacturer exists.

Price Is Only One Line of the Cost

A lower price per kilogram does not help if a batch is rejected, if documents are missing, or if a supplier cannot support a regulatory query. The total cost of a supplier includes audit effort, testing, documentation review and the time cost of delays. A buyer should compare suppliers on total cost of qualification and supply, not on the quoted price alone.

Planning a Supplier Change

Moving to a new API source is a project, not a purchase order. A sensible plan has four parts:

1. Compare specifications line by line. Look for differences in assay limits, impurity limits, particle size and moisture before any sample is ordered.
2. Run samples through your own process. Confirm blending, flow, dissolution or other behaviour that matters in your product.
3. Generate your own data. Many markets expect stability or comparability evidence when an API source changes for a registered product.
4. Check the regulatory route. Depending on the market, a source change may need a variation, supplement or notification. Allow time for it.

Starting this work early, while the current supplier is still performing, is what turns a second source from a theory into real supply security.

6. How India Fits Into Generic API Supply

India is central to global generic supply. According to the Government of India's Press Information Bureau (PIB), in India's Pharmaceuticals in Global Healthcare: From Domestic Production to International Markets (21 March 2026):

• India ranks 3rd globally by volume and 11th by value in pharmaceuticals.
• India is "the largest global supplier of generic medicines, accounting for around 20 per cent of global supply."
• Pharma exports stood at USD 30.5 billion in 2024–25, reaching 191 countries.
• There are "about 500 active pharmaceutical ingredient (API) manufacturers, accounting for nearly 8 per cent of the global API industry."
• Under the Production Linked Incentive (PLI) scheme for bulk drugs, manufacturing capacity of 55,100 metric tonnes per year was established for 26 critical APIs and key starting materials (as of September 2025), and the PLI schemes have avoided imports worth Rs. 3,591 crore of APIs, key starting materials and drug intermediates.

For a buyer, the practical meaning is a deep supplier base. India has hundreds of API manufacturers, and the quality range among them is wide. That makes supplier qualification more important, not less. The existence of many suppliers is an opportunity for a buyer who knows how to check them.

7. A Buyer's Checklist for Qualifying a Generic API Supplier

This checklist works for any API, and it is the practical answer to "how do I choose?"

1. Confirm the specification. Ask which pharmacopoeia and which edition the supplier tests against, and request the full specification, not only a grade name.
2. Request a batch-specific Certificate of Analysis. It should match the specification and name the batch, test methods and results.
3. Request the MSDS and Technical Data Sheet. These cover safety, handling and physical properties.
4. Ask for GMP and quality-system evidence. This can include GMP and ISO certificates. Confirm the issuing body and the validity date.
5. Ask about master-file availability. In the United States, a Drug Master File (DMF) is a submission a holder may choose to make to FDA, so its absence alone does not disqualify a supplier. Ask what the supplier can offer to support your own regulatory filing.
6. Check the elemental-impurity and residual-solvent data the supplier can provide, so you can complete your own risk assessment under ICH Q3D and related guidelines.
7. Ask about change control. How will the supplier notify you of changes to process, raw materials or site?
8. Test samples in your own process. Chemical conformity does not guarantee physical behaviour.
9. Check the supply record. Ask about typical lead times, batch size, minimum order quantity and packaging options.
10. Consider an audit or questionnaire. A remote or on-site review is the strongest way to verify a quality system.
11. Plan a second source. Qualify a backup before it is needed.

Keep a record of every document received and its date. Regulators and customers can ask for the file at any time.

How to Read a Certificate of Analysis Before You Trust It

A Certificate of Analysis (CoA) is the single most-used document in supplier qualification, and it is easy to skim. Check these points every time:

• Batch number and dates. The batch on the CoA must match the batch on the drums, and the manufacturing and retest or expiry dates must be shown.
• Tests against the specification. Each test should show the limit and the result, not only "complies."
• Method references. The CoA should name the pharmacopoeial or in-house method used.
• Authorisation. A named, authorised quality person should have released the batch.
• Consistency over time. Compare results across several batches. Stable, repeatable results say more about a supplier than one good CoA.

8. Mineral and Nutraceutical-Grade APIs: Where Generic Sourcing Is the Norm

Mineral salts such as ferrous fumarate, dried ferrous sulphate and di-calcium phosphate are long-established, widely available ingredients. They are made by many manufacturers and sold on the open market. There is no originator supply chain for these materials in the way there is for a patented new molecule. For formulators, that means the question is not "branded or generic?" but "which qualified supplier?"

Several features of this segment shape supplier choice:

• Compendial monographs exist. Ferrous Fumarate, for instance, has a USP-NF monograph, so buyers can specify a recognized standard.
• Physical properties matter. Particle size and moisture behaviour can affect tablet, capsule and fortification processes.
• Elemental impurities matter. Mineral and metal-salt ingredients are directly relevant to elemental-impurity control.
• End uses vary. The same ingredient may go into pharmaceutical, nutraceutical, food-fortification or animal-nutrition products, and the required grade and documents differ by use.

Buyers should confirm, product by product, which monograph and grade apply to their intended use and market.

One Ingredient, Several Document Sets

The same mineral salt can be bought for a pharmaceutical formulation, a dietary supplement, a food-fortification programme or an animal-nutrition premix. The chemistry is the same, but the grade, the pharmacopoeia or food standard, and the supporting documents are not. A buyer who states the end use and destination market up front, in the enquiry, avoids the common problem of receiving a technically correct material with the wrong paperwork. A good supplier will ask the same questions before quoting.

9. Shreeji Industries' Approach

Shreeji operates as a merchant-market manufacturer. It supplies to formulators in multiple countries, and its documentation is offered so that a buyer can run its own supplier qualification against the checklist in this guide. Minimum order quantity for Dried Ferrous Sulphate is 500 kg, and the company exports to more than 50 countries.

Where to Go Next

10. Common Misconceptions

Misconception 1: "A Generic API Is a Lower-Quality API"

Quality depends on the manufacturer's process, controls and documentation, not on whether the ingredient is branded. FDA states that generic medicines are manufactured under the same strict standards as brand-name medicines, and FDA inspects plants for compliance with good manufacturing practice regulations.

Misconception 2: "Same Molecule Means Same Material"

The molecule is the same. Impurity profile, particle size, moisture and residual solvents can still differ between suppliers.

Misconception 3: "The Cheapest Quote Is the Best Value"

Price per kilogram is one part of cost. Rejected batches, missing documents and delays often cost more than a small price difference.

Misconception 4: "One Approved Supplier Is Enough"

Single-source dependence is a risk. A qualified second source protects supply.

Misconception 5: "A Certificate Proves Everything"

A certificate is evidence, not proof. Check the issuing body, scope and validity date, and verify through audit where possible.

11. Frequently Asked Questions

12. Sources and References

Data sourced from regulatory authority websites, government publications and, where noted, industry associations.